Status:
UNKNOWN
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
Lead Sponsor:
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions:
Chemotherapy-induced Neutropenia
Myelosuppression
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000...
Eligibility Criteria
Inclusion
- Patients' age≥18 years old, male or female
- Diagnosis of non-myeloid malignant solid tumors
- Patients are planned to perform chemotherapy and preventive use the PEG-rhG-CSF or preventive or therapeutic use of rhG-CSF after chemotherapy
- Patients' mental status are well, could understand the study and willing to participate the study, sign the informed consent form
- The investigator believes that patients can benefit from this study
Exclusion
- Patients who have been confirmed to be allergic to Jinyouli® or rhG-CSF or its excipients
- Pregnant or lactating women and women who plan to be pregnant during clinical observation
- Other patients that the doctor believe not suitable for inclusion
Key Trial Info
Start Date :
February 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT03846414
Start Date
February 13 2019
End Date
October 1 2020
Last Update
February 19 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.